Business Context and Reporting Period
Company: Organon & Co.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Organon is a global healthcare company focused on women's health and general medicines. The company operates as a single operating segment with two reporting units: U.S. and International. Key products include Nexplanon, Follistim AQ, Hadlima, and Vtama.
Key Financial Metrics
| Metric ($ in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | 1,602 | 1,582 | 4,709 | 4,811 |
| Gross Profit | 857 | 923 | 2,572 | 2,819 |
| Gross Margin | 53.5% | 58.3% | 54.6% | 58.6% |
| Net Income | 160 | 359 | 392 | 755 |
| Diluted EPS | $0.61 | $1.38 | $1.50 | $2.92 |
| Operating Cash Flow (9M) | $559 (2025) vs $549 (2024) | |||
| Cash and Equivalents | $672 (as of Sept 30, 2025) | |||
| Total Debt (Principal) | $8,828 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Decline: Nine-month revenue decreased 2% year-over-year. Excluding foreign exchange, the decline was also 2%. This was driven by significant volume declines in Atozet (due to loss of exclusivity in France, Spain, and Japan), Singulair (price reductions in Japan/China), and Dulera (loss of customer contract and supply constraints).
- Profitability Compression: Net income for the nine months dropped 48% to $392 million. Gross margin contracted due to increased manufacturing optimization costs, unfavorable product mix, and amortization related to the Dermavant acquisition ($31 million in 9M 2025).
- Expense Management: R&D expenses decreased 19% year-over-year due to headcount reductions and the discontinuation of the OG-6219 clinical program. Restructuring costs increased to $88 million for the nine months ended Sept 30, 2025, compared to $23 million in the prior year, aimed at achieving $200 million in annual savings.
- Debt Reduction: The company repurchased and cancelled $242 million of its 5.125% notes due in 2031, recognizing a $42 million pre-tax gain. It also terminated the NovaQuest Funding Agreement, recognizing a $4 million gain.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Investigation Findings: An Audit Committee investigation revealed improper sales practices involving Nexplanon wholesalers in the U.S. during specific periods in 2022, 2024, and 2025. The company determined that without these practices, revenue would have fallen short of guidance. The company ceased these practices, which is expected to adversely impact Q4 2025 sales.
- Leadership Changes: Former CEO Kevin Ali resigned on October 26, 2025. Joseph Morrissey was appointed Interim CEO. The Board also appointed an Executive Chair and Lead Independent Director.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting related to "tone at the top" and information communication. Disclosure controls were deemed ineffective as of September 30, 2025.
- Divestiture: Subsequent to the reporting period, Organon agreed to divest the Jada System to Laborie Medical Technologies for up to $465 million.
Risks and Contingencies
- Legal Proceedings: Significant product liability litigation continues regarding Fosamax (femur fractures) and Nexplanon/Implanon. A Master Settlement Agreement was signed for New Jersey Fosamax cases.
- Regulatory and Tax: The "One Big Beautiful Bill Act" (OBBBA) was signed into law in July 2025, impacting interest deductibility and R&D expensing. The company is evaluating impacts for 2026 and beyond.
- Patent Expirations: Continued pressure from loss of exclusivity (LOE) on key products like Atozet and potential generic entry for Nexplanon in 2027.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of the remediation plan for material weaknesses in internal controls and the timeline for re-certification of effective controls.
- Nexplanon Sales Trajectory: Monitor Q4 2025 and full-year 2026 sales data to assess the true demand for Nexplanon absent the improper channel stuffing practices.
- Legal Exposure: Track developments in the Fosamax and Nexplanon litigation, particularly the impact of the New Jersey settlement and the Supreme Court's denial of the writ of certiorari regarding preemption.
- Debt Covenants: Confirm continued compliance with the Senior Credit Agreement leverage ratio covenants given the restructuring costs and revenue pressures.
- Regulatory Impact: Assess the long-term financial impact of the OBBBA tax provisions and potential FDA delays on the five-year duration indication for Nexplanon.